These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
251 related items for PubMed ID: 7769843
21. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology. Wang LM, White JC, Capizzi RL. Cancer Chemother Pharmacol; 1990; 25(6):418-24. PubMed ID: 2311169 [Abstract] [Full Text] [Related]
22. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Seymour JF, Huang P, Plunkett W, Gandhi V. Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215 [Abstract] [Full Text] [Related]
23. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Gandhi V, Plunkett W. Cancer Res; 1988 Jan 15; 48(2):329-34. PubMed ID: 3335008 [Abstract] [Full Text] [Related]
24. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH. Cancer Res; 2000 Nov 15; 60(22):6421-6. PubMed ID: 11103808 [Abstract] [Full Text] [Related]
25. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux. Chan TC. Cancer Res; 1989 May 15; 49(10):2656-60. PubMed ID: 2713849 [Abstract] [Full Text] [Related]
27. Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis. Wang Z, Van Tuyle G, Conrad D, Fisher PB, Dent P, Grant S. Cancer Res; 1999 Mar 15; 59(6):1259-67. PubMed ID: 10096557 [Abstract] [Full Text] [Related]
29. Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Cancer Res; 1987 Jun 01; 47(11):3005-11. PubMed ID: 3471322 [Abstract] [Full Text] [Related]
31. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Takemura H, Urasaki Y, Yoshida A, Fukushima T, Ueda T. Cancer Res; 2001 Jan 01; 61(1):172-7. PubMed ID: 11196156 [Abstract] [Full Text] [Related]
33. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution. Ross DD, Chen SR, Cuddy DP. Cancer Res; 1990 May 01; 50(9):2658-66. PubMed ID: 2328491 [Abstract] [Full Text] [Related]
36. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells. Richel DJ, Colly LP, Arkesteijn GJ, Arentsen-Honders MW, Kerster MG, ter Riet PM, Willemze R. Cancer Res; 1990 Oct 15; 50(20):6515-9. PubMed ID: 2208110 [Abstract] [Full Text] [Related]
37. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia. Jahns-Streubel G, Reuter C, Unterhalt M, Schleyer E, Wörmann B, Büchner T, Hiddemann W. Leukemia; 1995 Nov 15; 9(11):1857-63. PubMed ID: 7475275 [Abstract] [Full Text] [Related]
40. Methotrexate-induced changes in the levels of 1-beta-D-arabinofuranosylcytosine triphosphate in L1210 cells. Roberts D, Peck C, Hilliard S, Wingo W. Cancer Res; 1979 Oct 15; 39(10):4048-54. PubMed ID: 476642 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]